StockWatch
·

NITTA GELATIN INDIA LTD.-$

BSE: 506532

P/L Snapshot

Q1 FY27 · standalone

vs Q4 FY26·vs Q1 FY26
Revenue
144.54
-13.2%+2.3%
Expenditure
110.65
-8.1%-4.0%
Net Profit
25.19
-25.9%+30.0%
OPM %
24.46%
-3.60pp+4.66pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0046.6593.29139.94186.58Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Price Chart
Reports

Nitta Gelatin PAT +32% YoY to ₹25.2 Cr on cost relief; revenue flat, -13% QoQ

gelatin · collagen manufacturing · margin expansion

ResultsQ1 FY2731 Jul 20263 minMetals & Mining
Latest
Board Meeting31 Jul, 5:40 pm

Nitta Gelatin PAT +32% YoY to ₹25.2 Cr on cost relief; revenue flat, -13% QoQ

Nitta Gelatin India's consolidated net profit rose 31.6% year-on-year to ₹25.18 Cr in Q1 FY27 (quarter ended 30 June 2026), even as revenue from operations grew just 1.5% YoY to ₹140.87 Cr — making this a margin-led print rather than a volume or pricing story. The operating (EBITDA) margin expanded roughly 466 bps to 24.46% from 19.80% a year ago, and net profit margin rose to 17.42% from 13.54%, as net material cost (cost of materials consumed, adjusted for the inventory-build credit) eased to about 42.1% of revenue from 46.6% in the year-ago quarter — consistent with management's own note that the business's performance is dependent on raw-material quality, availability and price. There were no exceptional items in either this quarter or the year-ago comparator, so the 31.6% YoY PAT growth is a clean, unadjusted number. Standalone PAT of ₹25.19 Cr is nearly identical to the consolidated figure, confirming the small Bamni Proteins subsidiary carries negligible weight on the group result. Sequentially, the picture is softer: revenue fell 12.9% QoQ from Q4 FY26's ₹161.73 Cr and PAT fell 26.2% QoQ from ₹34.09 Cr, with OPM down from 28.06% and NPM down from 20.46%. This looks like a seasonal step-down and mild operating deleverage rather than a fresh cost problem — employee expense rose to 9.65% of revenue (from 7.82% in Q4) and other expenses to 23.80% (from 21.66%) as a broadly fixed cost base sat over a smaller Q1 revenue base, while the net-material-cost ratio itself was little changed QoQ (42.1% vs 42.5%). There is no management guidance or prior concall commentary on record to grade this print against, and no analyst/street coverage was found for this small-cap name, so both vsGuidance and vsStreet are unknown. The remaining quarter-relevant disclosures are governance/legal rather than financial: the board used the same meeting to approve a postal ballot for a KSIDC nominee-director change; Bamni Proteins (shut since a March 2024 Maharashtra Pollution Control Board closure order) stays classified as a discontinued operation with a marginal ₹0.10 Cr loss this quarter while the board explores disposing of its assets on a non-going-concern basis; and the company continues to carry an ₹18.20 Cr contingent liability on a customs-duty/fish-protein import-classification dispute now before the Supreme Court (interim stay granted, final hearing slated for September 2026), with no P&L impact this quarter.

31 Jul 2026, 05:40 pm

Corporate Events

Board MeetingNITTAGELA
2026
31Jul

Board Meeting

The 50th Annual General Meeting of the members of the Compan…

BSE Filing ↗
Board MeetingNITTAGELA
2026
30Jan

Board Meeting

Consider and approve the un-audited financial results (Stand…

BSE Filing ↗
Board MeetingNITTAGELA
2025
31Oct

Board Meeting

Consider and approve un-audited financial results (Standalon…

BSE Filing ↗
Board MeetingNITTAGELA
2025
1Aug

Board Meeting

consider and approve inter-alia the un-audited financial res…

BSE Filing ↗
Board MeetingNITTAGELA
2025
2May

Board Meeting

Consider and approve the standalone and consolidated audited…

BSE Filing ↗
Board MeetingNITTAGELA
2025
10Feb

Board Meeting

consider and approve the un-audited financial results (Stand…

BSE Filing ↗
Board MeetingNITTAGELA
2024
8Nov

Board Meeting

Consider and approve inter-alia the un-audited financial res…

BSE Filing ↗
DividendNITTAGELA
2024
10May

₹6 / share

BSE Filing ↗
Board MeetingNITTAGELA
2024
10May

Board Meeting

Consider and approve the standalone and consolidated audited…

BSE Filing ↗
Board MeetingNITTAGELA
2024
8Feb

Board Meeting

Consideration and approval of Un-Audited Financial Results (…

BSE Filing ↗
Board MeetingNITTAGELA
2023
10Nov

Board Meeting

Consider and approve the unaudited financial results (Standa…

BSE Filing ↗